Axalta Coating Systems Ltd. manufactures, markets and distributes coatings systems. The Company operates through two segments. Performance Coatings segment provides liquid and powder coatings solutions to both large regional and global original equipment manufacturers (OEMs) and to a fragmented and local customer base. The segment develops, markets and supplies a complete portfolio of coatings systems and color matching technologies. Mobility Coatings segment provides coatings technologies for light vehicle and commercial vehicle OEMs. The Company offers a comprehensive range of waterborne and solventborne products and systems used by the global automotive refinish industry to repair damaged vehicles. The Company’s industrial brands include Imron Industrial, Tufcote Industrial, Corlar Industrial, Strenex Industrial, PercoTop, Voltatex, AquaEC, Durapon, Hydropon, UNRIVALED, and Ceranamel for liquid coatings and Alesta, Teodur, Nap-Gard, Abcite and Plascoat for powder coatings.

Axalta Coating Systems Ltd.

AXIS Capital Holdings Limited is a holding company. The Company provides a range of specialty lines insurance and treaty reinsurance to its clients on a worldwide basis, through its subsidiaries and branch networks based in Bermuda, the United States, Europe, Singapore and Canada. Its underwriting operations are organized around two global underwriting platforms: AXIS Insurance and AXIS Re. The Company operates through two segments: Insurance and Reinsurance. Its Insurance segment offers specialty insurance products across various business lines. The product lines in this segment are property, marine, terrorism, aviation, credit and political risk, professional lines, liability, and accident and health. Its Reinsurance segment provides treaty reinsurance to insurance companies on a worldwide basis. The product lines in this segment are catastrophe, property, credit and surety, professional lines, motor, liability, engineering, agriculture, marine and aviation, and accident and health.

AXIS Capital Holdings Limited

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is developing and delivering novel therapies for the central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of the major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Its AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. Its AXS-07 is a multi-mechanistic, investigational medicine under development for the acute treatment of migraine.

Axsome Therapeutics, Inc.

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company's other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.

Gilead Sciences Inc.

Global X Lithium ETF (the Fund) seeks to provide investment results that correspond generally to the price and yield performance of the Solactive Global Lithium Index (the Index). The Index is free float adjusted, liquidity tested and market capitalization-weighted index that is designed to measure broad based equity market performance of global companies involved in the lithium industry, as defined by Structured Solutions AG. The Fund will normally invest at least 80% of its total assets in the securities of the Index and in depositary receipts based on the securities in the Index. The Fund will concentrate its investments (will hold 25% or more of its total assets) in a particular industry or group of industries to approximately the same extent that the Index is concentrated. The Index is sponsored by Structured Solutions AG, the index provider. The Fund’s investment adviser is Global X Management Company LLC.

Global X Lithium & Battery Tech ETF

Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer globally through the use of its proprietary tests, vast data sets and advanced analytics. The Company has developed its Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced-stage cancer. It also has developed Guardant360 TissueNext tissue test for advanced-stage cancer, Guardant Reveal blood test to detect residual and recurring disease in early-stage cancer patients, and Guardant360 Response blood test to predict patient response to immunotherapy or targeted therapy eight weeks earlier than current standard-of-care imaging. The Company’s GuardantINFORM platform is used to help biopharmaceutical companies accelerate precision oncology drug development through the use of this in-silico research platform to unlock further insights into tumor evolution and treatment resistance across various biomarker-driven cancers.

Guardant Health, Inc.

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. It develops T-cell therapies for solid tumors and has reported responses in multiple solid tumor indications. Its platform helps to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. Its cell therapy candidates include genetically engineered T-cell receptors (TCRs) and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. Its MAGE-A4 cell therapy franchise includes T-cell therapy products targeting solid tumor indications in which the MAGE-A4 antigen is expressed, with responses seen in eight indications (head and neck, esophagogastric junction, non-small cell lung cancer-squamous, synovial sarcoma, melanoma, urothelial, ovarian and myxoid/round cell liposarcoma indications).

Adaptimmune Therapeutics plc

Denali Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company’s clinical-stage programs include Antibody Transport Vehicle (ATV): triggering receptors expressed on myeloid cells 2 (TREM2), Protein Transport Vehicle (PTV): progranulin (PGRN), eukaryotic initiation factor 2 B (eIF2B), receptor-interacting serine/threonine protein kinase 1 (RIPK1), Enzyme Transport Vehicle (ETV): iduronate 2-sulfatase (IDS) and leucine-rich repeat kinase 2 (LRRK2), which are in various Phases ranging from Phase I through Phase III. The Company’s product candidates include DNL310, TAK-594/DNL593, TAK-920/DNL919, BIIB122/DNL151, DNL343, SAR443820/DNL788 and SAR443122/DNL758. The Company engineers its product candidates to cross the BBB, and act directly in the brain.

Denali Therapeutics Inc

Invivyd, Inc. is a biopharmaceutical company. It is focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases. It delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2 (COVID-19). Its technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify antibodies with a barrier to viral escape. It has a robust pipeline of antibody candidates for the prevention and treatment of COVID-19, including VYD222, a novel antibody. VYD222 is a monoclonal antibody candidate that has demonstrated in vitro neutralizing activity against dominant variants of concern, including XBB.1.5. VYD222 was engineered from adintrevimab (ADG20), which provided neutralizing protection against SARS-CoV-2 for all variants of concern until the emergence of the Omicron BA.2 strain and its sublineages.

INVIVYD INC

InvenTrust Properties Corp. is a multi-tenant retail real estate investment trust (REIT) that is focused on owning, leasing, redeveloping, acquiring and managing a multi-tenant retail platform. The Company owns, leases, redevelops, acquires, and manages grocery-anchored neighborhood and community centers, as well as power centers that often have a grocery component. It owns or had an interest in approximately 62 retail properties with a total gross leasable area (GLA) of approximately 10.3 million square feet, which includes four retail properties with a GLA of approximately 1.1 million square feet. The Company focuses on Sun Belt grocery-anchored neighborhoods and community centers. The Company’s subsidiaries include A-S 66 Beltway 8-Blackhawk, L.P., IA Arlington Riverview GP, L.L.C., IA Arlington Riverview Limited Partnership, IA Arlington Riverview LP, L.L.C., IA Atlanta Buckhead Member, L.L.C., IA Atlanta Buckhead, L.L.C., and IA Austin Scofield GP, L.L.C.

INVENTRUST PROPERTIES CORP

iShares Core S&P 500 ETF (the Fund) is an exchange-traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Standard & Poor’s 500 Index (the Index). The Index measures the performance of the large-capitalization sector of the United States equity market. The component stocks are weighted according to the total float-adjusted market value of their outstanding shares. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. The Fund invests in sectors, such as consumer non-cyclical, financial, energy, technology, communications, industrial, consumer cyclical, basic materials and utilities. BlackRock Fund Advisors (BFA) serves as the investment advisor to the Fund.

Core S&P 500 iShares ETF

Vanguard 500 Index Fund (the Fund) is an open-end investment company, or mutual fund. The Fund offers four classes of shares: Investor Shares, Admiral Shares, Signal Shares, and Exchange Traded Fund (ETF) Shares. The Fund seeks to track the investment performance of the Standard & Poor’s 500 Index, an unmanaged benchmark representing the United States large-capitalization stocks. The Fund employs a passive management-or indexing-investment approach designed to track the performance of the Standard & Poor’s 500 Index. The Fund attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index. 

S&P 500 Vanguard ETF

Tesla, Inc. designs, develops, manufactures, sells and leases fully electric vehicles and energy generation and storage systems, and offer services related to its products. The Company's automotive segment includes the design, development, manufacturing, sales, and leasing of electric vehicles as well as sales of automotive regulatory credits. Additionally, the automotive segment is also comprised of services and other, which includes non-warranty after-sales vehicle services, sales of used vehicles, retail merchandise, sales by its acquired subsidiaries to third party customers, and vehicle insurance. Its energy generation and storage segment include the design, manufacture, installation, sales and leasing of solar energy generation and energy storage products and related services and sales of solar energy systems incentives. Its automotive products include Model 3, Model Y, Model S and Model X. Powerwall and Megapack are its lithium-ion battery energy storage products.

Tesla, Inc.

Apple Inc. (Apple) designs, manufactures and markets smartphones, personal computers, tablets, wearables and accessories and sells a range of related services. The Company’s products include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, HomePod, iPod touch and accessories. The Company operates various platforms, including the App Store, which allows customers to discover and download applications and digital content, such as books, music, video, games and podcasts. Apple offers digital content through subscription-based services, including Apple Arcade, Apple Music, Apple News+, Apple TV+ and Apple Fitness+. Apple also offers a range of other services, such as AppleCare, iCloud, Apple Card and Apple Pay. Apple sells its products and resells third-party products in a range of markets, including directly to consumers, small and mid-sized businesses, and education, enterprise and government customers through its retail and online stores and its direct sales force.

Apple, Inc.

Microsoft Corporation is a technology company. The Company develops and supports software, services, devices, and solutions. Its segments include Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment consists of products and services in its portfolio of productivity, communication, and information services, spanning a variety of devices and platforms. This segment includes Office Consumer, LinkedIn, Dynamics business solutions, and Office Commercial. The Intelligent Cloud segment consists of its public, private, and hybrid server products and cloud services. This segment includes server products and cloud services, and enterprise services. The More Personal Computing segment consists of products and services, such as Windows, devices, gaming, and search and news advertising.

Microsoft Corporation

Vanguard Information Technology ETF seeks to track the investment performance of the MSCI US Investable Market Information Technology 25/50 Index, a benchmark of large-, mid-, and small-cap United States stocks in the information technology sector, as classified under the Global Industry Classification Standard (GICS). This GICS sector is made up of companies in three areas: technology software and services, including companies that develop software in various fields (such as the Internet, applications, systems, databases, and/or home entertainment), and companies that provide information technology consulting and services, data processing, and outsourced services; technology hardware and equipment, including manufacturers and distributors of communications equipment, computers and peripherals and electronic equipment, and semiconductors and semiconductor equipment manufacturers. The Vanguard Group, Inc. serves as advisor to the Fund through its Quantitative Equity Group.

Compare US

Compare AXSM vs. IVV

Overview

Performance

Industry & Region

Top Holdings

Industry & Region

Country Exposure

Industry Exposure